Register

Rheumatology

Gastroenterology   

Questions discussed in this category

How would you manage autoimmune pancreatitis in a patient after Whipple's procedure?
1 Answer available
How do you approach GI prophylaxis (e.g., PPIs, H2 blockers) in patients on long-term NSAIDs?
1 Answer available
How do you monitor patients with incidentally found high titer anti-smooth muscle antibodies without stigmata of liver disease?
2 Answers available
How do you manage calcium and vitamin D replacement in scleroderma and myositis patients with dysphagia and malabsorption?
1 Answer available
What is your approach to management of elevated liver enzymes in patients who recently started treatment with tocilizumab?
1 Answer available
What is your approach to pharmacologic treatment options in a patient with both SLE and Crohn's disease?
A female in her 50s with iatrogenic Cushing's Syndrome presenting for management of SLE with low disease activity (but not remission) in the setting o...
1 Answer available
How do you approach management of patients with active RA and recurrent non-severe C.diff?
(Patient with active RA despite hydroxychloroquine)
1 Answer available
Do you discontinue or adjust azathioprine when a patient develops elevated MCV after starting it?
When it seems fairly certain that this is a drug effect is it something that can just be monitored or requires a change in approach?
2 Answers available
How do you treat celiac disease associated inflammatory arthritis refractory to gluten free diet?
1 Answer available
Do you recommend checking anti-drug antibodies for patients on TNF inhibitors?
If so, how would positive levels guide your management?
2 Answers available


Papers discussed in this category

Medizinische Klinik (Munich, Germany : 1983), 2002-11-15
[Prevalence of circulating autoantibodies in healthy individuals].
Journal for scientific research. Medical sciences, 2001 Apr
Occurence of autoantibodies in healthy Omani individuals.
Arthritis Rheumatol, 2020 Apr 01
Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
Ann Rheum Dis, 2022 Jul 07
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus.

Related Topics in Rheumatology

Copyright © 2024 theMednet
All Rights Reserved.